Ipilimumab
FDA Approves Opdivo With Yervoy for Unresectable or Metastatic Hepatocellular Carcinoma
The FDA has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, Bristol Myers Squibb) for ...
APRIL 14, 2025
FDA Approves Opdivo With Yervoy for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer
The FDA has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, Bristol Myers Squibb) for ...
APRIL 9, 2025
10-Year Survival Rates Near 80% for Melanoma Patients Responding to Checkpoint Inhibitors
Two sets of 10-year outcome data from large multicenter trials with checkpoint inhibitors for the treatment of ...
NOVEMBER 27, 2024
Immunotherapy Before Surgery for Stage III Melanoma Significantly Improves Outcomes
After resection of stage III melanoma, adjuvant immunotherapy has previously been associated with a reduction in ...
JUNE 24, 2024
Study Supports Nivo-Ipi Combo Over Monotherapy for mRCC
The combination of nivolumab and ipilimumab may be more effective for treating metastatic renal cell carcinoma ...
AUGUST 17, 2017
Yervoy Approved for Pts 12 and Older With Unresectable or Metastatic Melanoma
The FDA approved impilimumab for pediatric patients 12 years and older with unresectable or metastatic melanoma.
JULY 25, 2017
AACR Report: More Immuno Rx Strategies for Advanced Melanoma
Washington—Combining checkpoint inhibitors yields an overall survival (OS) benefit in advanced melanoma, ...
JUNE 12, 2017
Checkpoint Inhibitors Advancing in Multiple GI Cancers
Immunotherapy with checkpoint inhibitors, specifically agents targeting programmed death-1 (PD-1), are advancing in ...
MAY 31, 2017
Bringing Immunotherapy For Melanoma to the Front Line
After working for Chevron Lubricants for 33 years as a laboratory chemist, Tom Bell was happy to retire in early ...
OCTOBER 19, 2016
